Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) CEO Abraham Ceesay sold 5,833 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $26.12, for a total value of $152,357.96. Following the completion of the transaction, the chief executive officer directly owned 562,080 shares in the company, valued at approximately $14,681,529.60. This trade represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Abraham Ceesay also recently made the following trade(s):

• On Tuesday, January 20th, Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock. The stock was sold at an average price of $26.11, for a total transaction of $132,717.13.
• On Wednesday, December 17th, Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock. The stock was sold at an average price of $29.63, for a total transaction of $150,609.29.
• On Wednesday, December 17th, Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock. The shares were sold at an average price of $29.64, for a total value of $172,890.12.
• On Monday, November 17th, Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock. The stock was sold at an average price of $25.20, for a total transaction of $128,091.60.
• On Monday, November 17th, Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock. The stock was sold at an average price of $25.19, for a total transaction of $146,933.27.

Rapport Therapeutics Stock Performance

NASDAQ:RAPP traded up $1.52 during trading hours on Thursday, reaching $27.92. The stock had a trading volume of 418,755 shares, compared to its average volume of 346,497. The stock has a market cap of $1.33 billion, a P/E ratio of -10.30 and a beta of 1.63. Rapport Therapeutics, Inc. has a 12-month low of $6.43 and a 12-month high of $42.27. The stock has a 50 day simple moving average of $28.47 and a 200 day simple moving average of $23.57.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06. On average, equities analysts expect that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research note on Thursday, January 8th. HC Wainwright lifted their price objective on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Wells Fargo & Company set a $51.00 price target on Rapport Therapeutics in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Wednesday, October 8th. Finally, BTIG Research restated a “buy” rating and issued a $47.00 price target on shares of Rapport Therapeutics in a research report on Monday, December 8th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.33.

Hedge Funds Weigh In On Rapport Therapeutics

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Rapport Therapeutics by 54.4% during the fourth quarter. SG Americas Securities LLC now owns 9,673 shares of the company’s stock valued at $293,000 after acquiring an additional 3,408 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Rapport Therapeutics during the 3rd quarter worth about $331,000. Maven Securities LTD purchased a new stake in shares of Rapport Therapeutics in the third quarter valued at approximately $594,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Rapport Therapeutics during the third quarter worth about $143,000. Finally, Vestal Point Capital LP purchased a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $28,215,000.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.